Results 121 to 130 of about 15,581 (231)
Structure of the Brd4 ET domain bound to a C-terminal motif from γ-retroviral integrases reveals a conserved mechanism of interaction [PDF]
, 2016 The bromodomain and extraterminal domain (BET) protein family are promising therapeutic targets for a range of diseases linked to transcriptional activation, cancer, viral latency, and viral integration.
Crowe, Brandon L. +5 more
core +2 more sources
Journal of Cell Communication and Signaling, Volume 20, Issue 1, March 2026.Abstract This study aims to explore the mechanism of action of the Bromodomain‐containing protein 4 (BRD4) inhibitor GNE‐987 in the treatment of pediatric T‐cell Acute Lymphoblastic Leukemia (T‐ALL), focusing on its effect in inhibiting T‐ALL cell proliferation by activating the HLA Complex P5 (HCP5) Super‐enhancer.
Xu Sang +6 more
wiley +1 more source
BET inhibition suppresses S100A8 and S100A9 expression in acute myeloid leukemia cells and synergises with daunorubicin in causing cell death [PDF]
, 2018 S100A8 and S100A9 are both members of the S100 family and have been shown to play roles in myeloid differentiation, autophagy, apoptosis, and chemotherapy resistance.
Chaudry, Sabah +4 more
core +2 more sources
Taming the Cytokine Storm: Therapeutic Strategies for Post‐Acute Sequelae of SARS‐CoV‐2 Infection
Health Science Reports, Volume 9, Issue 3, March 2026.ABSTRACT Background and Aim Post‐acute sequelae of SARS‐CoV‐2 infection (PASC), commonly referred to as long COVID, has emerged as a significant global health concern, marked by persistent symptoms and chronic inflammation following recovery from acute COVID‐19.
Emmanuel Ifeanyi Obeagu
wiley +1 more source
Targeting GLI factors to inhibit the Hedgehog pathway [PDF]
, 2015 Hedgehog (Hh) signaling has emerged in recent years as an attractive target for anticancer therapy because its aberrant activation is implicated in several cancers. Major progress has been made in the development of SMOOTHENED (SMO) antagonists, although
Alfonsi, Romina +4 more
core +2 more sources
MedComm, Volume 7, Issue 3, March 2026.Cancer remains the leading cause of mortality worldwide, and drug resistance further underscores the urgent need for innovative therapeutic strategies. Chromatin, a stable yet highly dynamic nucleoprotein complex, serves as the primary carrier of genetic material in eukaryotic cells.
Wentao Xia +4 more
wiley +1 more source
Altered regulation and expression of genes by BET family of proteins in COPD patients [PDF]
, 2017 Correction: PLoS One 2018 12 (4): 0175997Background BET proteins (BRD2, BRD3, BRDT and BRD4) belong to the family of bromodomain containing proteins, which form a class of transcriptional co-regulators.
Ahdesmaki, Miika J. +14 more
core +2 more sources
Targeting BET Bromodomains in Recalcitrant Cancers [PDF]
, 2017 Pancreatic and lung cancers have some of the worst five-year survival rates of all malignancies. These aggressive cancers are often diagnosed as metastatic disease and are refractory to therapeutic interventions. Driving mutations in these diseases are often therapeutic targets, but cancer cells evade death by circumventing the pathways targeted by ...
openaire +1 more source
Protein Lactylation in Cancer: Mechanisms and Therapeutic Targets
MedComm, Volume 7, Issue 3, March 2026.This schematic illustrates the central role of lactylation, a lactate‐derived posttranslational modification, in linking metabolic reprogramming to cancer progression and therapy resistance. At its core, lactylation modulates proteins, influenced by metabolic shifts and environmental factors.
Qianying Ouyang +10 more
wiley +1 more source
Epigenetics, 2018 The bromodomain and extra-terminal domain (BET) proteins are promising drug targets for cancer and immune diseases. However, BET inhibition effects have been studied more in the context of bromodomain-containing protein 4 (BRD4) than BRD2, and the BET ...
Lusy Handoko +13 more
doaj +1 more source